Related Experiment Video

Updated: Dec 17, 2025

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.6K

[Activity an enzyme 5`-nucleotidase in patients with chronic hepatitis C]

N V Galeeva1, I K Valeeva1

  • 1Kazan State Medical University.

Terapevticheskii Arkhiv
|June 30, 2020
PubMed

Insights

This study investigated 5`-nucleotidase activity in chronic hepatitis C patients, correlating it with disseminated intravascular coagulation (DIC) phases. Findings reveal enzyme activity changes across hypercoagulation, transient, and hypocoagulation stages.

Area of Science:

  • Biochemistry
  • Hepatology
  • Hematology

Background:

  • Chronic hepatitis C is a significant global health concern.
  • Disseminated intravascular coagulation (DIC) is a complex syndrome that can complicate chronic liver diseases.
  • Understanding the interplay between liver disease, coagulation, and specific enzyme activity is crucial for patient management.

Purpose of the Study:

  • To investigate the activity of the enzyme 5`-nucleotidase.
  • To correlate 5`-nucleotidase activity with different phases of disseminated intravascular coagulation (DIC) syndrome.
  • To examine the relationship between enzyme activity, DIC phases, and the duration of infection in chronic hepatitis C patients.

Main Methods:

  • Study included 166 patients (92 males, 74 females) diagnosed with chronic hepatitis C.
  • Patients were categorized into three groups based on platelet count (Tr) and hemostasis phases: hypercoagulation (Tr > 350×10^9/l), transient phase (Tr 350–200×10^9/l), and hypocoagulation (Tr < 200×10^9/l).
  • Enzyme 5`-nucleotidase activity was assessed in relation to these defined groups and infection duration.

Main Results:

  • Preliminary analysis indicates varying levels of 5`-nucleotidase activity across the identified DIC phases in chronic hepatitis C patients.
  • Enzyme activity demonstrates a discernible pattern related to the progression from hypercoagulation to hypocoagulation.
  • Further detailed results on the specific correlation with infection duration are pending comprehensive analysis.

Conclusions:

  • The activity of enzyme 5`-nucleotidase appears to be associated with the dynamic changes occurring during disseminated intravascular coagulation in chronic hepatitis C.
  • These findings suggest that 5`-nucleotidase may serve as a potential biomarker for monitoring coagulation status in patients with chronic hepatitis C.
  • Further research is warranted to elucidate the precise role and clinical implications of 5`-nucleotidase in this patient population.
Abstract

Keywords:
5`-nucleotidasechronic hepatitis Cdisseminated intravascular coagulation syndrome

More Related Videos

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.8K
A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.6K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
111
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
139
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
128